Symbiotec Pharmalab IPO Day 3 Live: NII jumped 135% - Check analysts view and more
- Symbiotec Pharmalab IPO reached 5.24x total subscription on Day 3.
- NII (bHNI) segment surged 135.0% intraday to hit 13.77x.
- Retail subscription jumped 80.5% to reach 5.00x.
- QIB participation remained flat at 0.59x.
- Issue closes on 2026-08-27 with listing expected on 2026-09-01.
*this image is generated using AI for illustrative purposes only.
Symbiotec Pharmalab’s IPO closed with a colossal late-stage surge, ending at 71.19x overall subscription. Qualified Institutional Buyers (QIB) drove the momentum, jumping sharply in the final hours to reach 172.03x. The Non-Institutional Individual (NII) category remained robust, while Retail interest also ticked up significantly by close.
Final Subscription Status
The issue ended its final day with significant momentum from institutional investors who accelerated bids sharply after 2 PM. The Non-Institutional Individual (NII) category remained strong, with bHNI leading individual demand.
| Category | Subscription Multiple |
|---|---|
| QIB | 172.03x |
| NII (bHNI) | 82.92x |
| NII (sHNI) | 54.98x |
| Retail | 12.84x |
| Employees | 15.29x |
| Overall | 71.19x |
Subscription Progression
Demand accelerated sharply throughout the four-day window. While early days saw modest interest, Day 4 brought a decisive institutional push that lifted the total multiple significantly from 37.95x to 71.19x in the final session.
| Day | Date | QIB | NII (bHNI) | NII (sHNI) | Retail | Total |
|---|---|---|---|---|---|---|
| Day 1 | 24-08-2026 | 0.35x | 1.56x | 0.77x | 0.94x | 0.79x |
| Day 2 | 25-08-2026 | 0.54x | 4.03x | 2.42x | 2.08x | 1.83x |
| Day 3 | 26-08-2026 | 0.59x | 13.77x | 11.11x | 5.00x | 5.24x |
| Day 4 | 27-08-2026 | 172.03x | 82.92x | 54.98x | 12.84x | 71.19x |
Intra-day Timeline (27-08-2026)
The standout move occurred between 11:15 AM and 4:15 PM, where QIB subscription raced ahead, more than tripling again in the final hours to reach 172.03x. Total subscription jumped +676.3% today (from 9.17x to 71.19x).
| Time (IST) | QIB | NII (bHNI) | Retail | Total |
|---|---|---|---|---|
| 11:15 | 0.63x | 23.10x | 6.76x | 9.17x |
| 12:15 | 2.01x | 28.88x | 8.07x | 12.07x |
| 13:15 | 10.40x | 35.50x | 9.18x | 17.19x |
| 14:15 | 17.62x | 32.34x | 6.47x | 18.36x |
| 15:15 | 63.13x | 49.55x | 11.38x | 37.95x |
| 16:15 | 172.03x | 54.52x | 12.40x | 70.94x |
| 17:15 | 172.03x | 54.98x | 12.84x | 71.19x |
About the Company
Symbiotec Pharmalab Limited is a research and development-driven pharmaceutical and biotechnology company. It holds a global leadership position in corticosteroid and steroidal-hormone APIs, with a 38.2% global volume market share in corticosteroids. Founded in 2002, the company operates as a CDMO for specialty pharmaceutical companies globally.
Financial Highlights
The company reported consistent revenue growth over the last three fiscal years. Total equity increased significantly, reflecting retained earnings and capital efficiency.
| Particulars | FY 2026 (₹ crores) | FY 2025 (₹ crores) | FY 2024 (₹ crores) |
|---|---|---|---|
| Revenue from Operations | 869.15 | 751.55 | 716.25 |
| Total Profit (PAT) | 109.90 | 96.79 | 100.06 |
| Total Equity | 1149.59 | 814.71 | 714.84 |
Objects of the Issue
- Prepayment and/or repayment of outstanding borrowings: ₹112.50 crores
- General corporate purposes: Balance net proceeds
Risk Factors
- High Revenue Concentration in APIs: 96.07% of revenue derived from API sales in Fiscal 2026.
- Regulatory Compliance Risks: Manufacturing facilities subject to inspections; recent US FDA Form 483 observations noted.
- Significant Export Revenue Exposure: 67.04% of revenue from external customers outside India in Fiscal 2026.
What's Next
- Allotment Date: 2026-08-28
- Listing Date: 2026-09-01
- Basis of Allotment: Pro-rata basis expected given high subscription multiples in NII and Retail categories.
How might the persistent lack of QIB interest (0.59x) impact the stock's liquidity and price stability in the initial weeks post-listing?
What are the potential implications for Symbiotec's export margins given the recent US FDA Form 483 observations and the heavy reliance on API sales?
Will the significant debt repayment of ₹112.50 crores sufficiently improve the company's balance sheet to offset risks associated with high customer concentration?
18
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
